



Allergic Contact Dermatitis: Pathology, Comorbidities, and Treatment

Guest Editor:

Dr. Francisco Navarro-Triviño

Contact Eczema and
Immunoallergic Diseases,
Dermatology Department,
Hospital Universitario San
Cecilio, Avda. del Conocimiento
s/n, 18016 Granada, Spain

Deadline for manuscript
submissions:

closed (30 September 2024)

Message from the Guest Editor

Allergic contact dermatitis (ACD) is a prevalent form of eczema that affects the general population, regardless of the age and or sex. The pathophysiology of ACD is very interesting given that each allergen can mediate a characteristic immune-mediated reaction. The use of immunomodulators during the week of the study may alter the results by blocking certain inflammatory pathways, such as inflammation mediated by Th2 lymphocytes. Comorbidities associated with ACD have not been specially studied. Although the treatment of ACD is avoidance of the detected allergen, topical and systemic treatments outside the technical specifications are sometimes required. We look forward to discussing these topics in this Special Issue.

- allergic contact dermatitis
- patch test
- pathophysiology
- comorbidities
- psychodermatosis
- treatment





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)